MARKET

RPRX

RPRX

Royalty Pharma Plc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

43.20
+2.12
+5.16%
After Hours: 43.09 -0.11 -0.25% 18:13 06/24 EDT
OPEN
41.50
PREV CLOSE
41.08
HIGH
43.56
LOW
41.20
VOLUME
8.18M
TURNOVER
0
52 WEEK HIGH
44.75
52 WEEK LOW
34.40
MARKET CAP
26.23B
P/E (TTM)
43.31
1D
5D
1M
3M
1Y
5Y
Royalty Pharma to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
NEW YORK, June 08, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022 at 2:20 p.m. ET. The webcast will be accessible fro...
GlobeNewswire · 06/08 12:30
Royalty Pharma plc's (NASDAQ:RPRX) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
It is hard to get excited after looking at Royalty Pharma's (NASDAQ:RPRX) recent performance, when its stock has...
Simply Wall St. · 06/04 12:22
Royalty Pharma to Present at the UBS Global Healthcare Conference 2022
NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the UBS Global Healthcare Conference 2022 on May 24, 2022 at 1:15 p.m. ET. The webcast will be accessible from Royalty Pharma’s ...
GlobeNewswire · 05/23 12:30
BRIEF-Royalty Pharma - New Capital Deployment Target Of $10-12 Billion Over The Next Five Years
reuters.com · 05/17 11:47
Royalty Pharma Investor Day Highlights Stronger Growth Outlook and the Power of Its Unique Business Model to Drive Value for All Stakeholders
New capital deployment target of $10-12 billion over the next five yearsOutlook for 2020-2025 Adjusted Cash Receipts (1) (non-GAAP) CAGR raised to 11-14%Adjusted Cash Receipts (1) (non-GAAP) expected to grow 10% or more over this decade, positioning Royalt...
GlobeNewswire · 05/17 11:00
Royalty Pharma Reports First Quarter 2022 Results
Net cash provided by operating activities (GAAP) of $460 million; Adjusted Cash Receipts(1) (non-GAAP) of $605 million Announced transactions of up to $450 million in Q1 20222022 guidance reaffirmed: Adjusted Cash Receipts(1) expected to be $2,225 to $2,30...
GlobeNewswire · 05/05 11:00
With Royalty Pharma plc (NASDAQ:RPRX) It Looks Like You'll Get What You Pay For
Royalty Pharma plc's ( NASDAQ:RPRX ) price-to-earnings (or "P/E") ratio of 41.8x might make it look like a strong sell...
Simply Wall St. · 05/04 19:32
Royalty Pharma Declares Second Quarter 2022 Dividend
NEW YORK, April 18, 2022 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2022 of $0.19 per Class A ordinary share. The dividend will be paid on June 15, 2022, ...
GlobeNewswire · 04/18 12:00
More
No Data
Learn about the latest financial forecast of RPRX. Analyze the recent business situations of Royalty Pharma Plc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

20.00%Strong Buy
70.00%Buy
10.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average RPRX stock price target is 52.44 with a high estimate of 58.00 and a low estimate of 47.00.
High58.00
Average52.44
Low47.00
Current 43.20
EPS
Actual
Estimate
0.200.400.600.80
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 314
Institutional Holdings: 281.53M
% Owned: 46.37%
Shares Outstanding: 607.18M
TypeInstitutionsShares
Increased
125
17.87M
New
48
4.35M
Decreased
59
15.51M
Sold Out
35
4.51M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+2.68%
Pharmaceuticals & Medical Research
+2.48%
Key Executives
Chairman/Chief Executive Officer/Director
Pablo Legorreta
Vice Chairman/Executive Vice President/Director
Christopher Hite
Chief Financial Officer/Executive Vice President
Terrance Coyne
Executive Vice President/Chief Scientific Officer
James Reddoch
Executive Vice President/General Counsel
George Lloyd
Executive Vice President
Marshall Urist
Lead Director/Independent Director
Henry Fernandez
Director
M. Germano Giuliani
Director
Rory Riggs
Independent Director
Bonnie Bassler
Independent Director
Errol De Souza
Independent Director
Catherine Engelbert
Independent Director
William Ford
Independent Director
Ted Love
Independent Director
Gregory Norden
No Data
No Data
About RPRX
Royalty Pharma plc is engaged in investing in late stage biopharmaceutical products. The Company invests in academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The Company’s portfolio of pharmaceutical investment includes investments in commercial products and development-stage product candidates. Its portfolio investments include AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko, Trikafta and OXLUMO.

Webull offers kinds of Royalty Pharma plc stock information, including NASDAQ:RPRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RPRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RPRX stock methods without spending real money on the virtual paper trading platform.